Cytori Therapeutics, Inc. (CYTX) At $0.36 Forms Bottom; Last Week Concordia International Corp. (CXRX) Coverage

Cytori Therapeutics, Inc. (CYTX) formed multiple bottom with $0.33 target or 8.00% below today’s $0.36 share price. Cytori Therapeutics, Inc. (CYTX) has $12.47M valuation. The stock decreased 4.05% or $0.015 during the last trading session, reaching $0.355. About 912,625 shares traded. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since January 18, 2017 and is downtrending. It has underperformed by 82.30% the S&P500.

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Tuesday, August 11 with “Buy”. The firm has “Hold” rating given on Monday, August 15 by GMP Securities. The rating was maintained by Scotia Capital with “Sector Outperform” on Tuesday, September 29. The firm has “Buy” rating by Laurentian given on Tuesday, March 29. The rating was upgraded by Scotia Capital to “Sector Perform” on Monday, September 19. The company was downgraded on Wednesday, February 8 by TD Securities. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Sector Perform” rating given on Monday, November 30 by IBC. As per Friday, October 16, the company rating was maintained by Scotia Capital. Mackie upgraded the stock to “Speculative Buy” rating in Monday, October 19 report. The company was reinitiated on Thursday, October 1 by RBC Capital Markets. See Concordia International Corp. (NASDAQ:CXRX) latest ratings:

09/08/2017 Broker: Canaccord Genuity Rating: Sell New Target: $1.0000 Maintain

The stock 0.43% or $0 during the last trading session, reaching $0.7. It is down 95.85% since January 18, 2017 and is downtrending. It has underperformed by 112.55% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $35.24 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Analysts await Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report earnings on March, 22. They expect $-0.07 earnings per share, up 70.83% or $0.17 from last year’s $-0.24 per share. After $-0.14 actual earnings per share reported by Cytori Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

Among 6 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Cytori Therapeutics has $1000 highest and $0.5 lowest target. $3.35’s average target is 843.66% above currents $0.355 stock price. Cytori Therapeutics had 11 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 11 by Maxim Group. The rating was maintained by TH Capital with “Buy” on Monday, August 10. The firm has “Hold” rating by Zacks given on Friday, September 4. The rating was downgraded by B. Riley & Co on Tuesday, July 25 to “Neutral”. The firm has “Buy” rating by Maxim Group given on Monday, July 10. Maxim Group maintained it with “Buy” rating and $1000 target in Wednesday, May 31 report. The rating was maintained by Maxim Group on Saturday, August 8 with “Buy”. Maxim Group maintained it with “Buy” rating and $1000 target in Monday, July 24 report.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: